CNS Probe Development, Validation and Utility in Drug R&D. What Have we Learnt from Small Molecules to Antibodies?

Presenter: Shil Patel, Ph.D. | Vice President, Experimental Medicine,  Codiak Biosciences

Developing disease-modifying therapies for central nervous system (CNS) disorders has historically been a low probability of success endeavor. The advent of molecular imaging approaches suitable for guiding drug research in this area has provided some guidance to more efficiently assess the suitability of drug candidates for further development along the R&D process. When implemented correctly, these imaging biomarkers have been used to provide go/no-go opportunities from early discovery into the clinical trial setting and beyond.

During this webinar, the presenter will:

  1. Provide historical context of using CNS imaging probes to develop drugs
  2. Highlight approaches used to de-risk which probe candidates to develop for clinical SPECT and PET and pin-pointing likely red flags
  3. Review examples of use of these probes to provide decision-making opportunities from the bench and into the clinic
Wednesday, October 14
9:00am EDT

Register for On-Demand Access:

Shil-patel_400x400-300x300

SHIL PATEL, PH.D.

Vice President, Experimental Medicine, Codiak Biosciences

Having completed his Ph.D. in Neuroscience from the University of Hertfordshire in the U.K. while working full-time at Merck, Dr. Patel has more than 30 years of experience in the pharmaceutical industry. His roles have ranged from initially developing in vitro, ex vivo and in vivo radioligand and pharmacological screens for CNS therapeutics to developing, validating novel CNS PET ligands. This has included the employment of multi-modal, non-invasive imaging modalities tracking small molecule, monoclonal antibody and antisense oligonucleotides (ASO) largely based on nuclear imaging in rodents and non-human primates. Having led and collaborated with multidisciplinary teams, one primary objective has been to utilize multi-modality imaging approaches to de-risk and drive therapeutic programs across several therapeutic areas, including neurology, neuroimmunology, oncology and hemophilia. His current role is heading up the Experimental Medicine group at Codiak Biosciences utilizing discovery and translational approaches to help drive the exosome platform towards and through the clinic.